- Home
- ZLAB vs EVT Comparison
ZLAB vs EVT Comparison
Compare ZLAB & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZLAB | EVT |
|---|---|---|
| Founded | 2013 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2017 | 2003 |
Fundamental Metrics
Financial Performance| Metric | ZLAB | EVT |
|---|---|---|
| Price | $19.77 | $27.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $49.60 | N/A |
| AVG Volume (30 Days) | ★ 888.8K | 103.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $460,156,000.00 | N/A |
| Revenue This Year | $9.75 | N/A |
| Revenue Next Year | $26.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.33 | N/A |
| 52 Week Low | $15.96 | $23.00 |
| 52 Week High | $41.20 | $27.96 |
Technical Indicators
Market Signals| Indicator | ZLAB | EVT |
|---|---|---|
| Relative Strength Index (RSI) | 62.65 | 54.32 |
| Support Level | $19.51 | $25.66 |
| Resistance Level | $20.25 | $27.36 |
| Average True Range (ATR) | 0.75 | 0.47 |
| MACD | 0.24 | 0.03 |
| Stochastic Oscillator | 99.24 | 57.41 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.